Category Archives: Cannabis Legalization

OTC Markets Group Welcomes Vapen MJ Ventures Corporation to OTCQX

OTC Markets Group Welcomes Vapen MJ Ventures Corporation to OTCQX

OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, today announced Vapen MJ Ventures Corporation (CSE: VAPN; OTCQX: VAPNF), a fully integrated agricultural technology, services and property management company in the cannabis industry, has qualified to trade on the OTCQX® Best Market.

Vapen MJ Ventures Corporation begins trading today on OTCQX under the symbol “VAPNF.”  U.S. investors can find current financial disclosure and Real-Time Level 2 quotes for the company on www.otcmarkets.com.

“We are pleased to welcome Vapen MJ Ventures Corporation to the OTCQX Best Market,” said Jason Paltrowitz, EVP of Corporate Services at OTC Markets Group. “Trading on the OTCQX Market in the U.S., along with the company’s recent listing on the Canadian Securities Exchange, will enable Vapen MJ Ventures Corporation to build visibility and provide additional transparency for investors globally. We look forward to supporting the company in the public markets.”

Thai Nguyen, chief executive officer, and Bob Brilon, president and chief financial officer of Vapen MJ Ventures Corporation added, “We believe that Vapen MJ’s qualification for trading on OTCQX will increase awareness and visibility while providing transparency for our global investors. Vapen MJ is expanding its market penetration in the United States with partnerships in various additional states. Simultaneously, the company is expanding its presence with the financial community, and joining the prestigious international community of companies that trade on OTCQX and increasing access for U.S. investors is a key step in this effort.”

SecuritiesLawUSA, PC acted as the company’s OTCQX sponsor.

About Vapen MJ Ventures Corporation
Vapen MJ Ventures Corporation, through its wholly-owned subsidiaries, currently operates as an agricultural technology, services and property management company utilizing a full vertical integration business model to oversee and execute all aspects of cultivation, extraction, manufacturing (THC and CBD cartridges, concentrates, edibles), retail dispensary, and wholesale distribution of high margin Cannabis THC and Hemp CBD products under the Vapen Brand. Vapen MJ currently provides these management and marketing services in the State of Arizona with expansion plans through acquisitions and partnerships worldwide. Vapen MJ expansion plans include partnering with cannabis license holders and hemp farms in multiple states within the U.S.

About OTC Markets Group Inc.
OTC Markets Group Inc. (OTCQX: OTCM) operates the OTCQX® Best Market, the OTCQB® Venture Market and the Pink® Open Market for 10,000 U.S. and global securities.  Through OTC Link® ATS and OTC Link ECN, we connect a diverse network of broker-dealers that provide liquidity and execution services.  We enable investors to easily trade through the broker of their choice and empower companies to improve the quality of information available for investors.

To learn more about how we create better informed and more efficient markets, visit www.otcmarkets.com.

OTC Link ATS and OTC Link ECN are SEC regulated ATSs, operated by OTC Link LLC, member FINRA/SIPC.

Subscribe to the OTC Markets RSS Feed

Media Contact:
OTC Markets Group Inc., +1 (212) 896-4428, media@otcmarkets.com

OTC Markets Group logo. (PRNewsFoto/OTC Markets Group)

Cision

View original content to download multimedia:http://www.prnewswire.com/news-releases/otc-markets-group-welcomes-vapen-mj-ventures-corporation-to-otcqx-300883876.html

SOURCE OTC Markets Group Inc.

Published at Fri, 12 Jul 2019 11:04:12 +0000

Plus Products Looks To Take Marketshare In A Pivotal U.S. Market

Plus Products Looks To Take Marketshare In A Pivotal U.S. Market

During the last year, we have noticed a significant increase the amount of demand for cannabis infused products and are bullish on this vertical of the cannabis industry. Over the next year, we expect this trend to persist and believe that the companies that are levered to this opportunity are poised to report massive growth.

Plus Products (PLUS.CN) (PLPRF) is a company that has been benefiting from the increasing consumer demand for cannabis infused products and this is an opportunity that we have been closely following.

The last two months have been significant for the cannabis infused product company and we are bullish on the growth prospects on a going-forward basis. During this time, Plus Products announced the acquisition of California cannabis concentrate business and reported plans to expand into the Nevada market. We are favorable on the growth prospects associated with these initiatives and will monitor how the team continues to execute on this.

Las Vegas Represents a Massive Market for Plus Products

Las Vegas is one of the most important cannabis markets in the US and we are favorable on the leverage that Plus Products has to this market. On an annual basis, Las Vegas attracts more than 42 million tourists, and this has made Nevada a primetime destination for cannabis businesses. When a company is working to build a national (or global) brand, they need to be focused on several key markets. These markets are similar in the way that they attract tourists and bring the people to the brand.

In late May, Plus Products announced plans to expand into the Nevada market through a definitive agreement to partner with TapRoot Holdings, a vertically integrated cannabis company with cultivation and manufacturing facilities in Las Vegas. When it comes to selection a strategic partner, Plus Products conducts significant due diligence and believes that it can leverage TapRoot’s extraction capabilities as a part of a supply agreement. In addition to TapRoot’s extraction capabilities, it has also received 7 of the 61 newly issued retail licenses in late 2018.

Plus Products believes that TapRoot has the facilities available for the company to easily and quickly deploy its machinery, ingredients, and personnel to ensure that the product remains consistent both in California and Nevada. As the company expands into new markets, it will serve as the manufacturing operations partner to ensure quality and consistency across markets. We find this to be significant when it comes to creating a consistent product and are bullish on the growth prospects associated with this relationship.

We are favorable on the leverage that Plus Products will have to the Las Vegas opportunity and believe that it is a key market when it comes to building an internationally recognized brand. We are of the opinion that the move into Nevada is just the start of something much bigger and this is a something that we are excited about. During the last year, Plus Products has become the top selling edible in the California market (according to BDS Analytics) and we expect its products to perform very well in cannabis markets across the US.

A Company with Massive Growth Potential

Last month, Plus Products announced that it has acquired an option to purchase Emerald Bay Wellness LLC, a California-based cannabis oil manufacturer. The option grants the company the irrevocable right, but not the obligation, to purchase all of the business assets of Emerald Bay Extracts for cash and stock.

There are a number of reasons why we are excited about this transaction and will highlight this one-by-one. First, Emerald Bay Extracts is currently one of Plus’ largest suppliers of cannabis oil and has been a supply partner for over a year. Second, if the option is exercised, the acquisition would give the company in-house cannabis extraction capabilities that would both improve quality control and increase gross margins on the core edibles business, while creating a new revenue stream and new product development capabilities. Finally, this transaction will provide attractive leverage to a burgeoning opportunity in California where the market is rapidly shifting towards manufactured products that require cannabis oil.

Another reason why we are bullish on the implications that this acquisition will have on the business is due to the cost of the transaction. Approximately 70% of the deal consideration would be subject to performance targets including revenue and we find this to be significant when it comes to execution. We are favorable on the vesting schedule associated with the acquisition and believe that it could significant advance Plus Products’ business.

A Company that is in a Class of its Own

One of the reasons we are favorable on Plus Products is due to the type of investors that it has attracted. During the last year, the company has received large investments from some of the most significant hedge funds that are focused on the cannabis industry and this is a testament to the quality of the opportunity.

When it comes to Plus Products, we believe that the company is led by one of the best management teams in the business and are favorable on the additions that have been made to the team. Since inception, the management team has proven its ability to execute and we are bullish on this aspect of the story. We believe that the strength of the management team played a key role in the company’s ability to attract strategic capital and find this to be significant.

Going forward, Plus Products has massive growth prospects and this is an opportunity to be watching. The planned expansion in Nevada will prove to be a major value driver and we expect to see the company enter additional US markets in the coming months. To learn more about how Plus Products plans to be a leading cannabis infused product company, please email support@technical420.com.

Pursuant to an agreement between StoneBridge Partners LLC and PLUS Products Inc. we have been hired for a period of 180 days beginning March 21, 2019 and ending September 21, 2019 to publicly disseminate information about (PLUS) including on the Website and other media including Facebook and Twitter. We are being paid $5,000 per month (CASH) per month for services rendered. We own 106,000 shares of (PLUS), which we purchased in via private placement. We may buy or sell additional shares of (PLUS) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. On November 1st 2018 StoneBridge Partners LLC sold 50,000 restricted shares of (PLUS) to a private investor via a direct sale.

Share

Share - Facebook


Share - Twitter

Authored By

Anthony Varrell

Anthony Varrell is Managing Director of StoneBridge Partners LLC. SBP continues to drive market awareness for leading firms in the cannabis industry throughout the U.S. and abroad.

Published at Fri, 12 Jul 2019 11:23:41 +0000

1933 Industries Increases Extraction Capacity for Concentrates in Nevada

1933 Industries Increases Extraction Capacity for Concentrates in Nevada

1933 Industries Inc. (CSE: TGIF) (OTCQX: TGIFF), a vertically integrated cannabis consumer packaged goods company that owns licensed cultivation and manufacturing assets to support its brands, reports on its expanded cannabis extraction capabilities and provides an update regarding its hemp extraction facility.

CSE: TGIF, OTCQX: TGIFF (CNW Group/1933 Industries Inc.)

Original AMA cultivation facility to be used for expanded extraction

The Company has commenced plans to utilize its original cultivation facility to increase its extraction capacity for concentrates. Concentrates such as shatter, crumble, sugar, wax, budder, and distillate are sold under the Alternative Medicine Association (AMA) brand and are available in licensed dispensaries throughout Nevada. Distillate is considered the cleanest, clearest and purest form of concentrate and yields high THC percentages. Well-known for its top-quality concentrates, AMA extracts its distillate by using a hydrocarbon extraction process. The Company has made preparations to complete tenant improvements on the building in order to expand its concentrate production area from 483 sq. ft. to 2,215 sq. ft. in the current facility. The expected distillate production capacity will increase from 40 litres per month to 80 litres per month, in order to secure the supply for its branded products as well as for its white label partners.

Once the plants are moved to the new cultivation facility, the Company expects to submit layout plans to the city of Las Vegas for permitting and commence tenant improvements on the original cultivation facility. The necessary extraction equipment has been sourced and will also be submitted to the state for approval. The Company expects the expanded operation to come online in the fall of 2019.

“This is another exciting development for the Company as we increase production of raw materials for our line of concentrates. We are growing, expanding and investing in infrastructure for the growth of our brands,” said Ms. Ester Vigil, President of the Company.

Hemp extraction facility will be one of a kind

The Company reports that it has been working with an engineering firm to customize the equipment that will be required to establish one of Nevada’s largest hemp extraction facilities, with increased output capacity and versatility for isolation of CBD, CBN, CBG, CBC, and several other cannabinoids, including the ability to produce full spectrum and broad-spectrum oils, as well as isolates, that meet required GMP standards.

Mr. Chris Rebentisch, CEO of the Company remarked, “The process has been scaled up after a lengthy research phase, where we aimed to create a method of extraction using specialized chemistry and equipment in order to obtain a higher yield of CBD, thus increasing our efficiency. The competitive advantage of the new facility will be the isolation of not only CBD but of additional individual cannabinoids at scale, which is unique and novel in the cannabis marketplace.”

He added, “The research phase served to engineer and customize our proprietary equipment for the desired scale of the pilot plant, therefore meeting the unique needs of our business. We believe that the capital investment we are making today will have the benefits of lowering our operating and manufacturing costs, increasing cannabinoid extraction efficiency with a higher recapture rate, and bringing higher returns for years to come.”

The Company has ordered its customized equipment and is working on the final layout of the facility and will commence tenant improvements once the floor plan and layout has received approval from the city of Las Vegas. Permitting has been completed for fire and city inspections as well as H-3 hazard zoning. Because the customized equipment requires a long lead time, the Company expects that the facility will be operational by year’s end.

The facility’s processing capacity is estimated at approximately 68,000 kgs. of hemp biomass or 150,000 lbs. per month, producing approximately 5,000 kgs. of full spectrum oils or 4,500 kgs. of CBD isolate.

About 1933 Industries Inc.
1933 Industries Inc. is a vertically integrated cannabis company with operations in the United States and Canada. 1933 Industries owns licensed medical and adult-use cannabis cultivation and production assets, proprietary hemp-based, CBD infused products, and CBD extraction services. Our proprietary brands include AMA, Canna Hemp™, Canna HempX™, Canna Fused™, Canna Hemp Paws™, and Nineteen 33 THC. Birdhouse Skateboards™, OG DNA Genetics, Denver Dab Co., The Real Kurupt’s Moon Rocks and Gotti’s Gold are under licensing agreements.

About Canna Hemp™
Canna Hemp™ CBD Relief Cream was named “Best Topical” by Leafy’s Best in State: The Top State Specific Products and Experiences of 2018. Infused’s award-winning transdermal Pain Relief Cream delivers fast-acting targeted relief to areas of discomfort, combating inflammation, arthritis joint pain, backaches, muscles spasms, strains, bruises, cramps, and headaches.
http://www.cannahemp.com
https://www.leafly.com/news/strains-products/best-in-state-2018-nevada-cannabis

About Canna HempX™
Canna Hemp X™ was named “Best Topicals for Pain” by Herb’s Guide to the Best Cannabis Products on the Planet. Canna Hemp X™ is a CBD sports recovery cream for athletes to help focus on recovery and wellness. From soothing pain, aiding with muscle spasms, healing assistance for bruises, injuries, or arthritis relief, Canna Hemp X™ bridges the gap between recovery and top performance.
http://www.cannahempx.com

https://herb.co/learn/best-cannabis-products/

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

Notice regarding Forward Looking Statements: This news release contains forward-looking statements. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct.  Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this news release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents, which can be found under the Company’s profile on www.sedar.com.   1933 Industries undertakes no obligation to update publicly or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by law.

Cision

View original content to download multimedia:http://www.prnewswire.com/news-releases/1933-industries-increases-extraction-capacity-for-concentrates-in-nevada-300883913.html

SOURCE 1933 Industries Inc.

View original content to download multimedia: http://www.newswire.ca/en/releases/archive/July2019/12/c1488.html

Alexia Helgason, Corporate Communications Director, 604-674-4756 (ext. 1), alexia@1933industries.com; Chris Rebentisch, CEO & Director, 604-674-4756 (ext. 1)Copyright CNW Group 2019

Published at Fri, 12 Jul 2019 12:40:42 +0000

Spectrum Therapeutics partners with Canadian Mental Health Association’s Not Myself Today® initiative

Spectrum Therapeutics partners with Canadian Mental Health Association’s Not Myself Today® initiative

Spectrum Therapeutics, the medical division of Canopy Growth Corporation (TSX: WEED) (NYSE: CGC) is pleased to announce a partnership with the Canadian Mental Health Association. The initiative, a first of its kind for a leading cannabis company and a national mental health organization, will see the CMHA in collaboration with Spectrum Therapeutics develop an educational content module related to cannabis in the workplace as part of CMHA’s Not Myself Today workplace mental health program. The module, slated to launch early next year, will feature a host of physical and digital engagement tools aimed to reduce stigma in the workplace on the use of cannabinoid based medicines. In addition, it will encourage greater healthcare practitioner oversight when patients use cannabis to treat a medical condition. The content will also include video resources featuring medical cannabis subject matter experts and fact sheets that provide detailed information and direct readers to further resources.

Spectrum Therapeutics partners with Canadian Mental Health Association's Not Myself Today® initiative (CNW Group/Spectrum Therapeutics)

“The stigma surrounding medical cannabis and mental illness prevents meaningful action and dialogue among those affected. One of the goals of this partnership is to break that stigma by empowering conversations about mental health informed by evidence-based educational resources,” said Dr. Mark Ware, Chief Medical Officer, Canopy Growth. “For Spectrum Therapeutics, this partnership presents a powerful opportunity to improve lives by enhancing physical and mental health through access to education that sparks learning along with conversations about medical cannabis in the workplace.”

Estimates suggest one in two Canadians have or will have a mental illness by age 40.[1] Fifty-three percent of Canadians consider anxiety and depression to be epidemic in the country[2] and mental illness is a leading cause of disability claims in the workplace in Canada.

Not Myself Today is an evidence-based initiative designed to help employers and employees transform mental health at work. The program is embraced by more than 500 organizations across Canada and the U.S., reaching more than 350,000 employees. By breaking down barriers and making the topic of mental health engaging and accessible to all employees, Not Myself Today improves mental health literacy, reduces stigma, and shifts workplace culture to be more supportive of every employee’s mental health and well-being. For the past six years, the initiative has evolved into a highly-regarded program and counts many of Canada’s largest and most respected employers across corporate, government and social sectors as its champions.

“The mental health-care system of the future is not just in clinics or hospitals—it’s in settings like the workplace, where we can promote the skills, knowledge and practices that can improve mental health for the broad population instead of limiting our focus to individual patients,” said Fardous Hosseiny, interim National CEO, CMHA. “With the support of partners like Spectrum Therapeutics, our Not Myself Today program will educate, reduce stigma, and foster safe and supportive cultures for the one in five Canadians who experience mental illness in a given year—and for the five in five Canadians who have mental health.”

The research on cannabis use and mental illness is still in its infancy and CMHA highlights that more studies are needed to understand the relationship between mental health and cannabis use, both in terms of possible benefits and risks. CMHA and Spectrum Therapeutics strongly advise that individuals speak with a health-care practitioner for advice on any mental health treatment including medical cannabis.

Spectrum Therapeutics has identified mental health as an area with high unmet medical needs and is currently engaged in clinical research in partnership with leading academic institutions and research centres to determine the role cannabis can play in addressing mood and anxiety disorders. Today’s announcement builds on Spectrum Therapeutics and Canopy Growth’s legacy of furthering the public’s understanding of cannabis which includes partnerships with the likes of:

  • Parent Action on Drugs and Canadian Students for Sensible Drug Policy to educate parents, adult caregivers and youth on how to make responsible decisions about cannabis.
  • The Arthritis Society to create evidence-based resources to help people with arthritis learn more about the potential of medical cannabis as a treatment.
  • The University of British Columbia by way of a $2.5 million donation to conduct controlled trials examining the potential utility of cannabis in addressing the opioid overdose crisis and to establish the Canopy Growth Professorship of Cannabis Science.
  • Mothers Against Drunk Driving (MADD) and the Canadian Drug Policy Coalition to conduct an extensive research review that formed the basis for MADD Canada’s recommendations on responsible cannabis use and sober driving.

Through these partnerships and support for campaigns such as Not Myself Today, Canopy Growth and its medical division, Spectrum Therapeutics is proud to provide education for patients, their families and healthcare providers on medical cannabis and its role in mitigating some of our most common healthcare issues.

Here’s to Future Growth (and promoting mental wellness).

About Canadian Mental Health Association
Founded in 1918, the Canadian Mental Health Association (CMHA) is the most established, most extensive community mental health organization in Canada. Through a presence in more than 330 communities across every province and one territory, CMHA provides advocacy, programs and resources that help to prevent mental health problems and illnesses, support recovery and resilience, and enable all Canadians to flourish and thrive. For more information, visit cmha.ca.

About Canopy Growth Corporation
Canopy Growth (TSX:WEED, NYSE:CGC) is a world-leading diversified cannabis, hemp and cannabis device company, offering distinct brands and curated cannabis varieties in dried, oil and Softgel capsule forms, as well as medical devices through Canopy Growth’s subsidiary, Storz & Bickel GMbH & Co. KG. From product and process innovation to market execution, Canopy Growth is driven by a passion for leadership and a commitment to building a world-class cannabis company one product, site and country at a time. Canopy Growth has operations in over a dozen countries across five continents.

Canopy Growth’s medical division, Spectrum Therapeutics is proudly dedicated to educating healthcare practitioners, conducting robust clinical research, and furthering the public’s understanding of cannabis, and has devoted millions of dollars toward cutting edge, commercializable research and IP development. Spectrum Therapeutics sells a range of full-spectrum products using its colour-coded classification Spectrum system as well as single cannabinoid Dronabinol under the brand Bionorica Ethics.

Canopy Growth operates retail stores across Canada under its award-winning Tweed and Tokyo Smoke banners. Tweed is a globally recognized cannabis brand which has built a large and loyal following by focusing on quality products and meaningful customer relationships.

From our historic public listing on the Toronto Stock Exchange and New York Stock Exchange to our continued international expansion, pride in advancing shareholder value through leadership is engrained in all we do at Canopy Growth. Canopy Growth has established partnerships with leading sector names including cannabis icons Snoop Dogg and Seth Rogen, breeding legends DNA Genetics and Green House Seeds, and Fortune 500 alcohol leader Constellation Brands, to name but a few. Canopy Growth owns 12 licensed cannabis production sites with millions of square feet of production capacity, including more than one million square feet of GMP certified production space. For more information visit www.canopygrowth.com

About Spectrum Therapeutics
Spectrum Therapeutics, the medical division of Canopy Growth Corporation (TSX: WEED, NYSE: CGC), is dedicated to educating healthcare practitioners, furthering the public’s understanding of medical cannabis and its various applications, and cutting edge, commercializable research and IP development. Founded in Canada, Spectrum Therapeutics operates in Australia, South America, Africa and across Europe. Its products are available in a wide range of potencies and formats designed to simplify the dialogue around strength and dosage by applying a colour-coded spectrum to categorize medical cannabis according to THC and CBD levels.

Spectrum Therapeutics’ offerings include whole flower cannabis, oils and new innovations such as Softgels in addition to single cannabinoid medicine Dronabinol under the brand Bionorica Ethics. Through product simplification, robust clinical research and ongoing education of healthcare professionals, Spectrum Therapeutics is committed to addressing the unmet medical needs of patients around the globe.

Notice Regarding Forward Looking Statements
This news release contains “forward-looking statements” within the meaning of the United States Private Securities Litigation Reform Act of 1995 and “forward-looking information” within the meaning of applicable Canadian securities legislation. Often, but not always, forward-looking statements and information can be identified by the use of words such as “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Forward-looking statements or information involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Canopy Growth or its subsidiaries to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements or information contained in this news release. Examples of such statements include “aimed to reduce stigma in the workplace on the use of cannabis as a medicine”, and “content will also include video resources featuring medical cannabis subject matter experts and fact sheets”. Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information, including content development and such risks contained in the Company’s annual information form dated June 24, 2019 and filed with Canadian securities regulators available on the Company’s issuer profile on SEDAR at www.sedar.com. Although the Company believes that the assumptions and factors used in preparing the forward-looking information or forward-looking statements in this news release are reasonable, undue reliance should not be placed on such information and no assurance can be given that such events will occur in the disclosed time frames or at all. The forward-looking information and forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking information or forward-looking information to reflect new information, subsequent events or otherwise unless required by applicable securities laws.

Cision

View original content to download multimedia:http://www.prnewswire.com/news-releases/spectrum-therapeutics-partners-with-canadian-mental-health-associations-not-myself-today-initiative-300882249.html

SOURCE Spectrum Therapeutics

View original content to download multimedia: http://www.newswire.ca/en/releases/archive/July2019/10/c4138.html

Canopy Growth, Carly Pickett, Media Relations, carly.pickett@canopygrowth.com, 343-996-3234; Tyler Burns, Investor Relations, Tyler.burns@canopygrowth.com, 855-558-9333 ex 122; Canadian Mental Health Association, Katherine Janson, National Director of Communications, Canadian Mental Health Association, National, kjanson@cmha.ca, 416-646-5557 ext. 24923Copyright CNW Group 2019

Published at Wed, 10 Jul 2019 12:04:53 +0000

Relevium Signs Exclusivity Agreement With SOSCannabis.com for Reimbursement for Pediatric Patients

Relevium Signs Exclusivity Agreement With SOSCannabis.com for Reimbursement for Pediatric Patients

Relevium Technologies Inc. (TSX.V: “RLV”, OTCQB: “RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”), announced today it has executed an exclusivity agreement to partner with SOS cannabis Inc. (“SOSCannabis”), which will provide pediatric customers with the ability to obtain free legal representation to seek reimbursement for the costs of medical cannabinoid therapy from different government agencies for the treatment of medical conditions for pediatric patients.

The partnership agreement will provide Relevium’s pediatric customers with access to an experienced legal and case management team, who will prepare the case file and seek retroactive and prospective reimbursement for parents of pediatric patients at no cost. The agreement provides Relevium with a unique advantage in terms of its business development strategy and first to market positioning in terms of pediatric applications.

Mr. Aurelio Useche, CEO of Relevium stated: “As we prepare to enter the pediatric endo-medicinal market in Canada with an initial ten (10) CannaKids® formulated products, not only are we providing parents with a natural alternative and/or health support mechanism, but now we are able to provide them with the ability to seek reimbursement from governmental agencies without any costs,” Mr. Useche stated further: “We are extremely happy to work with a team of caring legal professionals that can represent our customers in minimizing the financial burden of cannabinoid therapy.”

Maitre Robert Astell, President of SOSCannabis.com stated “We are delighted to welcome Relevium into our family of medicinal cannabinoid therapy suppliers. The focus and quest of Relevium in terms of pediatric patients is admirable and we look forward to onboarding parents into our fully-automated registration platform and to provide them with the state-of-the-art case management service in fulfilling their need for economic assistance in providing natural medicine to their children.”

Tracy Ryan, CEO of Cannakids® stated: “For years patients have struggled with the high expenses that come along with using cannabis as a medicine. Especially parents to sick children who often lose their jobs due to countless hospital stays and doctor’s appointments. This new opportunity for families is a major step in the right direction. We are elated that more will now have the opportunity to afford this powerful, non-toxic option that we have seen bring unimaginable relief to patients on a global scale.”

About S.O.S Cannabis
SOSCannabis.com is a multi-disciplinary law firm headquartered in Québec, Canada whose objective is to help people that use medical cannabis prescribed by a doctor to seek retroactive and prospective monetary reimbursement through claims made to governmental organizations. SOS Cannabis also provides referral services to a network of medical professionals and medical cannabis suppliers. The company counts with an experienced legal and administrative team to support medical claims with the provincial and federal governments.

About Cannakids®
CannaKids.org is a privately held company that has provided CO2 extracted, lab tested cannabis oil products to thousands of patients over the past 4 years. Using nurse guided assistance, the brand has been synonymous with some of the most recognized patient success stories in the world.

About Relevium Technologies
Relevium is a publicly-traded company that operates in the health and wellness industry, including legal cannabis, with a primary focus on online distribution. The principal business of the Company is the identification, evaluation, acquisition and operation of brands and businesses in the health and wellness markets and medical cannabis. The Company pursues its business strategy through an acquisition and partnership model in a holistic approach to encompass a wide range of health and wellness consumer products. Relevium operates through two wholly owned subsidiaries:

BGX E-Health LLC (BGX), based in Orlando, Florida, markets dietary supplements, nutraceuticals, sports nutrition and cosmeceuticals primarily through its Bioganix® brand portfolio in the US and Europe. Relevium’s premium brands are sold at some of the world’s largest retailers including Walmart.com and Amazon.com.

Biocannabix Health Corporation (BCX), based in Montreal, Quebec, is a biopharma nutraceutical company focused on delivering pediatric endo-medicinal nutraceuticals for cannabinoid therapy.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Cautionary Note Regarding Forward-Looking Statements
This release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian and United States securities laws. All statements in this news release, other than statements of historical facts, including statements regarding future estimates, plans, objectives, assumptions or expectations of future performance, are forward-looking statements and contain forward-looking information. Generally, forward- looking statements and information can be identified by the use of forward-looking terminology such as “intends” or “anticipates”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “should”, or “would” occur. Forward-looking statements are based on certain material assumptions and analysis made by the Company and the opinions and estimates of management as of the date of this press release. These forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information.

Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward- looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial outlook that are incorporated by reference herein, except in accordance with applicable securities laws. We seek to rely on the applicable safe harbor.

On Behalf of the Board of Directors

RELEVIUM TECHNOLOGIES INC.

Aurelio Useche
President and CEO

For more information about this press release:
Tel: +1.888.528.8687
Email: investors@releviumcorp.com Website: www.releviumtechnologies.com

https://www.facebook.com/releviumcorp/
https://ca.linkedin.com/company/relevium-technologies-inc-
https://twitter.com/releviumcorp?lang=en

Share

Share - Facebook


Share - Twitter

Authored By

Anthony Varrell

Anthony Varrell is Managing Director of StoneBridge Partners LLC. SBP continues to drive market awareness for leading firms in the cannabis industry throughout the U.S. and abroad.

Published at Wed, 10 Jul 2019 15:55:01 +0000

Canopy Growth Announces Acquisition of KeyLeaf Life Sciences to Support Long-Term Major Scale Extraction Needs

Canopy Growth Announces Acquisition of KeyLeaf Life Sciences to Support Long-Term Major Scale Extraction Needs

Canopy Growth Corporation (TSX:WEED, NYSE:CGC) is pleased to announce that it has completed a transaction to acquire Saskatoon-based bio-product extractor KeyLeaf Life Sciences, related entities, and intellectual property. Canopy Growth has been working closely with KeyLeaf – formerly known as POS Bio-Sciences – as a trusted partner building out extraction processes and technology for the past year as it refines its scale extraction model for Canadian and global markets. As previously disclosed, Canopy Growth assumed control of KeyLeaf for accounting purposes in November 2018. As such, KeyLeaf’s financial results were consolidated in the Company’s fiscal 2019 financial statements. Through the transaction the Company is acquiring a large-scale Canadian extraction facility as well as an extraction-related facility in the United States to support the Company’s U.S. CBD expansion.

With over 45 years of experience in the canola, nutraceutical, cosmetic, and bio-product industries, KeyLeaf is a recognized leading authority with significant intellectual property relating to plant-based extraction and ingredients. The extensive experience of KeyLeaf’s chemists, engineers, and operators will remain within the organization to further refine the cannabinoid extraction process and will support Canopy Growth in the design, training, oversight, and implementation of additional extraction sites around the world.

KeyLeaf has been working closely with Canopy Growth over the past year to retrofit its Saskatchewan facility to advance technology development and commercialization, in order to process hemp and cannabis biomass, and to conduct pre- and post-extraction processes. It is anticipated the facility, which is currently in the Health Canada licensing process, will be able to process up to 5,000 kg of input materials daily when operational.

Canopy Growth intends to leverage this facility, along with other owned and partner extraction options, to process its over 5,000 acres of Canadian CBD hemp production, over 160 acres of outdoor cannabis production, as well as any extraction materials outputted from its over 4 million square feet of greenhouse growing operations. Then it’s off to Smiths Falls to produce the best possible, IP-protected products out there!

Additionally, the acquisition includes KeyLeaf’s ingredient science and innovation industrial scale facility in Batavia, Illinois. The Batavia facility focuses on short path distillation and the concentration of key compounds, ensuring that the output is free of impurities in products intended for consumption and currently holds several certifications, including a US FDA Food Facility Registration, as well as a state hemp processing licence, and Silliker GMP and Food Safety Systems Audit. As the Company builds its U.S. operations, this facility will be key in executing our program to bring CBD products to market in the U.S. by the fourth quarter of fiscal 2020 and will process the extract required to provide Canopy Growth with the supply needed to sustain these products.

“The KeyLeaf operations and team deliver instant scale at a pivotal stage in our growth, with brand new products coming to market later this year requiring sophisticated extraction capabilities at scale,” said Bruce Linton, Chairman & co-CEO, Canopy Growth Corporation. “This acquisition is the result of a year’s worth of work with a trusted partner, and part of our commitment to always staying a step ahead as leaders in a nascent industry, focused on the long-game one piece at a time.”

Here’s to Future (extracted) Growth.

About Canopy Growth Corporation
Canopy Growth (TSX:WEED, NYSE:CGC) is a world-leading diversified cannabis, hemp and cannabis device company, offering distinct brands and curated cannabis varieties in dried, oil and Softgel capsule forms, as well as medical devices through Canopy Growth’s subsidiary, Storz & Bickel GMbH & Co. KG. From product and process innovation to market execution, Canopy Growth is driven by a passion for leadership and a commitment to building a world-class cannabis company one product, site and country at a time. Canopy Growth has operations in over a dozen countries across five continents.

Canopy Growth’s medical division, Spectrum Therapeutics is proudly dedicated to educating healthcare practitioners, conducting robust clinical research, and furthering the public’s understanding of cannabis, and has devoted millions of dollars toward cutting edge, commercializable research and IP development. Spectrum Therapeutics sells a range of full-spectrum products using its colour-coded classification Spectrum system as well as single cannabinoid Dronabinol under the brand Bionorica Ethics.

Canopy Growth operates retail stores across Canada under its award-winning Tweed and Tokyo Smoke banners. Tweed is a globally recognized cannabis brand which has built a large and loyal following by focusing on quality products and meaningful customer relationships.

From our historic public listing on the Toronto Stock Exchange and New York Stock Exchange to our continued international expansion, pride in advancing shareholder value through leadership is engrained in all we do at Canopy Growth. Canopy Growth has established partnerships with leading sector names including cannabis icons Snoop Dogg and Seth Rogen, breeding legends DNA Genetics and Green House Seeds, and Fortune 500 alcohol leader Constellation Brands, to name but a few. Canopy Growth operates eleven licensed cannabis production sites with over 4.7 million square feet of production capacity, including over one million square feet of GMP certified production space. For more information visit www.canopygrowth.com

Notice Regarding Forward Looking Statements
This news release contains “forward-looking statements” within the meaning of the United States Private Securities Litigation Reform Act of 1995 and “forward-looking information” within the meaning of applicable Canadian securities legislation. Often, but not always, forward-looking statements and information can be identified by the use of words such as “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Forward-looking statements or information involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Canopy Growth or its subsidiaries to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements or information contained in this news release. Examples of such statements include statements with respect to future product format offerings and throughput capabilities. Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information, including the Company’s ability to satisfy provincial sales contracts or provinces purchasing all cannabis allocated to them, and such risks contained in the Company’s annual information form dated June 27, 2018 and filed with Canadian securities regulators available on the Company’s issuer profile on SEDAR at www.sedar.com. Although the Company believes that the assumptions and factors used in preparing the forward-looking information or forward-looking statements in this news release are reasonable, undue reliance should not be placed on such information and no assurance can be given that such events will occur in the disclosed time frames or at all. The forward-looking information and forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking information or forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities laws.

About KeyLeaf
KeyLeaf Life Sciences is a global ingredient and process technology company established over 45 years ago. Headquartered in Saskatoon, Saskatchewan, KeyLeaf is recognized around the world as a trusted expert in plant-based bioprocessing. KeyLeaf has worked with over 800 companies from 40 countries and continues to increase Saskatchewan’s global visibility as a hub for innovation.

Canopy Growth Announces Acquisition of KeyLeaf Life Sciences to Support Long-Term Major Scale Extraction Needs (CNW Group/Canopy Growth Corporation)

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/canopy-growth-announces-acquisition-of-keyleaf-life-sciences-to-support-long-term-major-scale-extraction-needs-300875362.html

SOURCE Canopy Growth Corporation

View original content to download multimedia: http://www.newswire.ca/en/releases/archive/June2019/26/c0418.html

Canopy Growth Corporation Contact: Caitlin O’Hara, Media Relations, Caitlin.Ohara@canopygrowth.com, 613-291-3239; Investor Relations, Tyler Burns, Tyler.Burns@canopygrowth.com, 855-558-9333 ext. 122; KeyLeaf Life Sciences Contact: Justin White, Vice-President Global Sales and Business Development, 306-978-2800Copyright CNW Group 2019

Source: Canada Newswire (June 26, 2019 – 9:00 AM EDT)

News by QuoteMedia
www.quotemedia.com

Share

Share - Facebook


Share - Twitter

Published at Wed, 26 Jun 2019 13:23:07 +0000

Aurora Cannabis Prepared for Expansion of Canada’s Cannabis Market

Aurora Cannabis Prepared for Expansion of Canada’s Cannabis Market

Aurora Cannabis Inc. (“Aurora” or the “Company”) (NYSE: ACB) (TSX: ACB), the Canadian company defining the future of cannabis worldwide, today announced its plans for the highly-anticipated expansion of the consumer cannabis market into vapes, concentrates, and edibles. The Company is also preparing to launch a national public awareness campaign this fall, educating consumers, provinces and retailers about the safe usage and consumption of these new derivative products.

Aurora Polaris, a 300,000 square foot Centre of Excellence for value-add products, packaging and international logistics at the Edmonton International Airport. Polaris is anticipated to be fully operational by the end of 2019. Initial operations will commence in October 2019. (CNW Group/Aurora Cannabis Inc.)

Through a combination of new and enhanced facilities, Aurora intends to produce new, high-quality products across the country in a variety of product categories. Aurora recently entered into a supply agreement with PAX Labs Inc., a leading consumer technology brand in cannabis. With the PAX partnership, the Company will have the market leading PAX Era device to compete in the Closed Loop category and will also launch a new range of vape products, at various price points, targeted to all major consumer markets through both 510 thread cartridges and disposable single-use units.

“Aurora is the world’s leading producer of high-quality cannabis and we’re ready to introduce high-value product additions to this improved, federally legal market,” said the Company’s CEO Terry Booth. “From the beginning, we’ve invested in industry-leading production and distribution technology, and in consumer research to drive products to market that consumers will desire. These things, together with the dynamic partnerships we’ve entered into on the accessory and technology fronts, position us well for this new market launch in December as per Health Canada’s recent regulatory amendments.”

On the issue of product education and awareness, Booth said: “We will show leadership when it comes to educating consumers on the safe, responsible consumption of cannabis edibles. Over the next few months we will be rolling out educational campaigns across Canada to help provide consumers with the information they need to make safe and sound decisions.”

To support the successful launch of vapes, concentrates, and edibles products, and to continue to ensure sufficient supply for domestic and international markets, Aurora has established production hubs in Western Canada, on the same federal property as Aurora Sky at the Edmonton International Airport, and in Eastern Canada at Aurora River, in Bradford, Ontario and at Aurora Vie in Pointe-Claire, Quebec near Montréal. These centres will provide centralized production, packaging, logistics and distribution capabilities. In total, they comprise more than 450,000 square feet and are strategically located to efficiently distribute our products to markets across the country.

Aurora Air, a 20,000 square foot manufacturing facility, is now in the final stages of receiving its Health Canada license. Located near the Edmonton International Airport and Aurora Sky, Air will be home to several of the new production lines for edible products. New industrial extraction systems have also been installed at Aurora Sky and Aurora River.

About Aurora

Headquartered in Edmonton, Alberta, Canada with funded capacity in excess of 625,000 kg per annum and sales and operations in 24 countries across five continents, Aurora is one of the world’s largest and leading cannabis companies. Aurora is vertically integrated and horizontally diversified across every key segment of the value chain, from facility engineering and design to cannabis breeding and genetics research, cannabis and hemp production, derivatives, high value-add product development, home cultivation, wholesale and retail distribution.

Highly differentiated from its peers, Aurora has established a uniquely advanced, consistent and efficient production strategy, based on purpose-built facilities that integrate leading-edge technologies across all processes, defined by extensive automation and customization, resulting in the massive scale production of high-quality consistent product. Intended to be replicable and scalable globally, our production facilities are designed to produce cannabis of significant scale, with high quality, industry-leading yields, and low per gram production costs. Each of Aurora’s facilities is built to meet European Union Good Manufacturing Practices (“EU GMP”) standards. Certification has been granted to Aurora’s first production facility in Mountain View County, the MedReleaf Markham facility, and its wholly owned European medical cannabis distributor Aurora Deutschland. All Aurora facilities are designed and built to the EU GMP standard.

In addition to the Company’s rapid organic growth and strong execution on strategic M&A, which to date includes 17 wholly owned subsidiary companies – MedReleaf, CanvasRX, Peloton Pharmaceutical, Aurora Deutschland, H2 Biopharma,  BC Northern Lights, Larssen Greenhouses, CanniMed Therapeutics, Anandia, HotHouse Consulting, MED Colombia, Agropro, Borela, ICC Labs, Whistler, and Chemi Pharmaceutical – Aurora is distinguished by its reputation as a partner and employer of choice in the global cannabis sector, having invested in and established strategic partnerships with a range of leading innovators, including: Radient Technologies Inc. (TSXV: RTI), Hempco Food and Fiber Inc. (TSXV: HEMP), Cann Group Ltd. (ASX: CAN), Micron Waste Technologies Inc. (CSE: MWM), Choom Holdings Inc. (CSE: CHOO), CTT Pharmaceuticals (OTCC: CTTH), Alcanna Inc. (TSX: CLIQ), High Tide Inc. (CSE: HITI), EnWave Corporation (TSXV: ENW), Capcium Inc. (private), Evio Beauty Group (private), and Wagner Dimas (private).

Aurora’s Common Shares trade on the TSX and NYSE under the symbol “ACB”, and are a constituent of the S&P/TSX Composite Index.

For more information about Aurora, please visit our investor website, investor.auroramj.com

Terry Booth, CEO
Aurora Cannabis Inc.

Forward looking statements

This news release includes statements containing certain “forward-looking information” within the meaning of applicable securities law (“forward-looking statements”). Forward-looking statements are frequently characterized by words such as “plan”, “continue”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “may”, “will”, “potential”, “proposed” and other similar words, or statements that certain events or conditions “may” or “will” occur, and include, but are not limited to, the completion of the launch of the vape and edibles products, the successful launch of the public education campaign,   and the completion of licensing for the Air facility. These statements are only predictions. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking statements throughout this news release, including, but not limited to consumer demand for the new products. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law

Neither TSX, NYSE nor their applicable Regulation Services Providers (as that term is defined in the policies of the Toronto Stock Exchange and New York Stock Exchange) accept responsibility for the adequacy or accuracy of this release.

Cision

View original content to download multimedia:http://www.prnewswire.com/news-releases/aurora-cannabis-prepared-for-expansion-of-canadas-cannabis-market-300872730.html

SOURCE Aurora Cannabis Inc.

Published at Fri, 21 Jun 2019 20:34:41 +0000

Cardiol Therapeutics Announces Plans for Orphan Drug Program in Acute Myocarditis with CardiolRx CBD Formulation

Cardiol Therapeutics Announces Plans for Orphan Drug Program in Acute Myocarditis with CardiolRx CBD Formulation

Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF), a leader in the research and commercial development of pharmaceutical cannabidiol (CBD) and targeted therapies for heart disease, is pleased to announce that the Company is planning an international clinical trial in acute myocarditis utilizing its CardiolRx CBD formulation.

CardiolRx is Cardiol’s pure pharmaceutically-produced CBD. Designed to be the safest and most consistent formulation on the market, CardiolRx is cGMP certified and does not contain any THC. The Company plans to commercialize CardiolRx pharmaceutical CBD during 2019 in the billion-dollar market for medicinal cannabinoids in Canada and is pursuing market introduction opportunities in Europe and Latin America. Cardiol’s acute myocarditis program provides a unique opportunity to build brand awareness in support of this commercial launch and is being designed by an independent Steering Committee comprised of thought leaders in cardiology from North America and Europe.

Acute myocarditis is characterized by inflammation of the heart muscle (myocardium). The most common cause is viral infection of the heart tissue which is initially responsible for the inflammation. In most cases, the virus clears, and inflammation subsides, but in a significant number of cases the inflammation persists with ongoing myocardial damage and depressed heart function. Although the symptoms are often mild, myocarditis remains an important cause of acute and fulminant heart failure and is the most common cause of sudden cardiac death in people less than 35 years old. In addition, some patients proceed to develop chronic dilated cardiomyopathy which continues to be the leading indication for cardiac transplantation. Although viral causes of myocarditis are the most common, myocarditis can result from a broad range of infections and can be caused by drugs including chemo-therapeutic agents used to treat several common cancers. Symptoms include chest pain, fatigue, shortness of breath, and arrhythmias. Myocarditis damages heart cells, reducing overall heart function as measured by left ventricular ejection fraction such that the heart does not pump sufficient blood to meet the needs of the body.

Based on the large body of experimental evidence of the powerful anti-inflammatory activity of CBD in models of cardiovascular disease, Cardiol believes there is a significant opportunity to develop a potential breakthrough therapy for acute myocarditis that would be eligible for designation as an orphan drug. In the United States, an orphan drug designation is granted for pharmaceuticals being developed to treat medical conditions affecting fewer than 200,000 people. These conditions are referred to as orphan diseases. The assignment of orphan status to a disease and to drugs developed to treat it is a matter of public policy in many countries and has yielded medical breakthroughs that might not otherwise have been achieved. In the U.S. and the European Union, orphan drugs are eligible for accelerated marketing approvals and companies developing orphan drugs typically receive other incentives, including a prolonged period of market exclusivity that can extend over seven years, during which the drug developer has sole rights to market the drug.

“The U.S. orphan drug program was successfully utilized to accelerate the first FDA approval of CBD for the treatment of rare forms of pediatric epilepsy and significant shareholder value was created in the process,” stated David Elsley, President and CEO of Cardiol Therapeutics. “Given the mortality and the significant morbidity risk associated with acute myocarditis, we believe there is a similar opportunity in pursuing an expedited development program of our CardiolRx pharmaceutical CBD formulation for this serious orphan disease which has no accepted standard of care.”

About Cardiol Therapeutics

Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) is a leader in producing 100% pure pharmaceutical CBD and developing groundbreaking therapies for heart disease. The Company is focused on commercially launching the safest and most consistent CBD products for consumers and healthcare providers in the multi-billion-dollar medicinal cannabinoid markets. Cardiol is utilizing nanotechnologies designed to deliver CBD and other anti-inflammatory drugs for the treatment of heart failure. Heart failure is a leading cause of death and hospitalization in North America, with associated healthcare costs exceeding US$30 billion annually in the U.S. alone. For further information about Cardiol, please visit the Company’s website at www.cardiolrx.com.

For further information, please contact:

David Elsley, President & CEO
905.491.6793
david.elsley@cardiolrx.com

Trevor Burns, Investor Relations
905.491.6791
trevor.burns@cardiolrx.com

Cautionary statement regarding forward-looking information:

This news release contains “forward-looking information” within the meaning of applicable Canadian securities laws which may include, but is not limited to, statements with respect to: future events; the future performance or the intended business strategy of Cardiol Therapeutics Inc. (“Cardiol”); the potential for Cardiol’s licensed drug encapsulation and delivery technologies to enhance the bioavailability of pharmaceuticals; management’s expectations regarding estimated future pharmaceutical research and development opportunities, collaborations and prospects; the success and proposed timing of Cardiol’s product development activities, including, but not limited to, the proposed timeline of Cardiol’s product candidate pipeline for commercial introduction; the ability of Cardiol to develop its product candidates; Cardiol’s plans to research, discover, evaluate and develop additional products; Cardiol’s proposed future collaborations to advance Cardiol’s lead nanoformulations into clinical development; and the potential for Cardiol’s cannabinoid-based products to provide sources of future revenue. All statements, other than statements of historical fact, that address activities, events or developments that Cardiol believes, expects or anticipates will, may, could or might occur in the future are “forward-looking information”.

Forward-looking information is frequently identified by the use of words such as “plans”, “expects”, “projects”, “intends”, “believes”, “anticipates”, “forecasts”, and other similar words and phrases, including variations (and negative variations) of such words and phrases, or may be identified by statements to the effect that certain

actions, events or conditions “may”, “could”, “should”, “would”, or “will” be taken, occur or be achieved. Forward-looking information contained herein reflects the current expectations or beliefs of Cardiol based on information currently available to it and is subject to a variety of known and unknown risks and uncertainties and other factors that could cause the actual events or results to differ materially from any future results, performance or achievements expressed or implied by the forward-looking information. These risks and uncertainties and other factors include that the success of Cardiol’s product candidates will require significant capital resources and years of clinical development efforts; the results of clinical testing and trial activities of Cardiol’s products; Cardiol’s ability to obtain regulatory approval and market acceptance of its products; Cardiol’s ability to raise capital and the availability of future financing; Cardiol’s lack of operating history; unforeseeable deficiencies in the development of Cardiol’s product candidates; uncertainties relating to the availability and costs of financing needed in the future for Cardiol’s research and development initiatives;

Cardiol’s ability to manage its research, development, growth and operating expenses; the potential failure of clinical trials to demonstrate acceptable levels of safety and efficacy of Cardiol’s product candidates; Cardiol’s ability to retain key management and other personnel; risks related to fluctuations in medicinal cannabinoid markets

in Canada and worldwide; uncertainties regarding Cardiol’s ongoing collaborative and manufacturing partnerships; uncertainties regarding results of researching and developing products for human use; Cardiol competes in a highly competitive and evolving industry; Cardiol’s ability to obtain and maintain current and future intellectual property protection; and other risks and uncertainties and factors. These risks, uncertainties and other factors should be considered carefully, and investors should not place undue reliance on the forward-looking information. Any forward-looking information speaks only as of the date on which it is made and, except as may be required by applicable securities laws, Cardiol disclaims any intent or obligation to update or revise such forward-looking information, whether as a result of new information, future events or results or otherwise. Although Cardiol believes that the expectations reflected in these forward-looking statements are reasonable, they do involve certain assumptions, risks, and uncertainties and are not (and should not be considered to be) guarantees of future performance. It is important that each person reviewing this news release understands the significant risks attendant to the operations of Cardiol.

Corporate Logo

Corporate Logo

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/45767

Share

Share - Facebook


Share - Twitter

Authored By

Anthony Varrell

Anthony Varrell is Managing Director of StoneBridge Partners LLC. SBP continues to drive market awareness for leading firms in the cannabis industry throughout the U.S. and abroad.

Published at Thu, 20 Jun 2019 17:31:23 +0000

CannTrust Establishes U.S. Operations

CannTrust Establishes U.S. Operations

Today, CannTrust Holdings Inc. (TSX: TRST, NYSE: CTST), a federally regulated licensed producer of medical and recreational cannabis with more than 72,000 patients in Canada, announced that it is establishing operations in the United States (“U.S.”), starting in the State of California. CannTrust has signed a non-binding letter of intent (“LOI”) that will provide access to over 3,000 acres of farmland for hemp production with Elk Grove Farming Company, LLC (“Elk Grove”), a diversified farming company with operations in the State of California, to secure low-cost hemp with high cannabidiol (“CBD”) content. CannTrust and Elk Grove will each have 50% ownership of a new entity (the “Joint Venture”).

CannTrust Holdings Inc. (CNW Group/CannTrust Holdings Inc.)

The opportunity in the U.S. for CannTrust is to become a trusted supplier of consistent, standardized and high-quality hemp-derived CBD formulations at scale. The Company believes there will be increasing demand for hemp-derived CBD formulations from international retailers and product manufacturers, and those organizations require expertise in genetics and value-add processing to ensure products are desirable and meet the highest safety standards.

CannTrust will guarantee the off-take of biomass produced by the Joint Venture, and will use its expertise to process, formulate and sell hemp-derived CBD products in U.S. markets where such sales are lawful. As an experienced operator meeting rigorous regulatory standards, CannTrust is well positioned to execute on this cultivation, processing and formulation strategy with the goal of becoming a leading supplier of hemp-derived CBD products in the U.S.

“This agreement represents another bold move for CannTrust. Our U.S. operation is expected to deliver a significant increase in low-cost production capacity, which will leverage our expertise in standardized CBD-based product formulation, and will give the Company a foothold in the largest international CBD market in the world with an experienced and knowledgeable partner,” said Peter Aceto, Chief Executive Officer. “Following our successful equity offering, we have the liquidity we need to fund our ambitious growth plans including our greenhouse expansion in Niagara, our outdoor cultivation operation in British Columbia, our global footprint expansion and now our U.S. operation. We continue to focus on delivering on our vision of becoming a global provider of innovative cannabis-based and hemp-derived products.”

Elk Grove has multi-generational experience in farming across a wide variety of commodities and value-added expertise in leading crop protection products, application and input supply with operations throughout the State of California. The team at Elk Grove specializes in consulting on agricultural development and has unique knowledge of farming in California, one of the most prolific agricultural regions in the world.

“We are thrilled to be partnering with CannTrust. Our knowledge of farming operations in California coupled with CannTrust’s expertise in developing award-winning formulations is the perfect match to become a trusted supplier of CBD products in the U.S,” said Morgan Houchin of Elk Grove Farming Company, LLC.

CannTrust U.S. Operations
This initiative is the first step in CannTrust’s development of full-scale U.S. operations. Upon establishment of the Joint Venture in California, CannTrust will have secured a long-term source of significant supply of low-cost industrial hemp from a trusted and proven partner. Prior to commercial scale cultivation from the Joint Venture in 2020, the Company plans to execute on (1) its processing strategy from the biomass produced from the Joint Venture, and (2) its product development strategy.

CannTrust is well positioned to use extracted product from its U.S. operations in proprietary products that have already been developed and that are ready for commercial production (e.g., CannTrust’s patented single-serve beverage pods), products currently under development with existing partners, and in formulations required by future partners.

Investment in the U.S. operation is expected to be up to $20 million through to the end of 2020. This capital investment includes the Company’s share of cultivation, harvest and post-harvest processing for the Joint Venture, as well as extraction and processing investments that will be funded by CannTrust. This level of capital investment assumes starting with up to 300 acres for cultivation in 2020.

Details of the LOI
The Joint Venture will secure a long-term lease for over 3,000 acres of farmland designated for hemp production in Southern California, which is currently wholly-owned by the Houchin family or through partnership investment. CannTrust will provide its expertise in grow methodology, drying techniques, and experience in extraction, as well as provide genetics that are legal under state and federal law. Elk Grove will lead operations, farm management services, packaging and transportation, and provide suitable land area and warehouse space for drying and value-added handling of the hemp biomass produced.

Both parties will provide equal contribution of capital to finance operations of the Joint Venture, including capital investments, operating expenditures and working capital. All profits will be distributed based on ownership percentage of the Joint Venture.

Upon execution of a binding agreement, commercial operation of the Joint Venture is targeted to begin in 2020, subject to local regulatory approval.

Regulatory Framework
The California Industrial Hemp Farming Act became effective in January 2017.  The federal Agricultural Improvement Act of 2018 became effective January 2019, removing hemp from Schedule I of the Federal Controlled Substances Act, thereby removing industrial hemp, which is defined as having less than 0.3% THC content, as a federally regulated controlled substance.

In the State of California, growers of industrial hemp for commercial purposes must register with the county agricultural commissioner prior to cultivation; there is currently no state registration required to grow industrial hemp.

CannTrust, Elk Grove and the Joint Venture intend to develop its cultivation and processing operations according to both federal and state laws.

About CannTrust
CannTrust is a federally regulated licensed producer of medical and recreational cannabis in Canada. Founded by pharmacists, CannTrust brings more than 40 years of pharmaceutical and healthcare experience to the medical cannabis industry and serves more than 72,000 medical patients with its dried, extract and capsule products. The Company operates its Niagara Perpetual Harvest Facility in Pelham, Ontario, and prepares and packages its product portfolio at its manufacturing centre of excellence in Vaughan, Ontario. The Company has also purchased 81 acres of land in British Columbia and expects to secure over 200 acres of land in total for low-cost outdoor cultivation which it will use primarily for its extraction-based products.

About Elk Grove
Elk Grove Farming Company, LLC is a diversified farming and farm management company with headquarters in Bakersfield, California.  Elk Grove is a company owned by Tech Agricultural Corporation and the Houchin family.  Tech Agricultural Corporation also offers industry leading crop protection products and application, adaptable financing for crop production and input supply, agricultural real estate brokerage and investment services, custom farm management, corn and alfalfa seed distribution and dairy mineral supplements.

Forward Looking Statements
This press release contains “forward-looking information” within the meaning of Canadian Securities laws and “forward-looking statements” within the meaning of the United States Private Securities Litigation Reform Act of 1995 and other applicable United States safe harbor laws, and such statements are based upon CannTrust’s current internal expectations, estimates, projections, assumptions and beliefs and views of future events. Forward-looking information and forward-looking statements can be identified by the use of forward-looking terminology such as “believes”, “expect”, “likely”, “may”, “will”, “should”, “intend”, “anticipate”, “potential”, “proposed”, “estimate” and other similar words, including negative and grammatical variations thereof, or statements that certain events or conditions “may”, “would” or “will” happen, or by discussions of strategy.

The forward-looking information and statements in this news release include statements relating to the Company’s plans to reach a definitive agreement with Elk Grove as it relates to the Joint Venture, the timing of commercial production of the Joint Venture and the anticipated demand for hemp-based CBD formulations. Forward-looking information and statements necessarily involve known and unknown risks, including, without limitation: finalizing the Joint Venture; risks associated with general economic conditions; adverse industry events; loss of markets; future legislative and regulatory developments in Canada, the United Statesand elsewhere; the cannabis industry in Canada generally; and, the ability of CannTrust to implement its business strategies.

Any forward-looking information and statements speak only as of the date on which they are made, and, except as required by law, CannTrust does not undertake any obligation to update or revise any forward-looking information or statements, whether as a result of new information, future events or otherwise. New factors emerge from time to time, and it is not possible for CannTrust to predict all such factors. When considering these forward-looking information and statements, readers should keep in mind the risk factors and other cautionary statements in CannTrust’s Annual Information Form dated March 28, 2019 (the “AIF”) and filed with the applicable Canadian securities regulatory authorities on SEDAR at www.sedar.com and filed as an exhibit CannTrust’s Form 40-F annual report under the United States Securities Exchange Act of 1934, as amended, with the United States Securities and Exchange Commission on EDGAR at www.sec.gov. The risk factors and other factors noted in the AIF could cause actual events or results to differ materially from those described in any forward-looking information or statements.

The TSX and NYSE do not accept responsibility for the adequacy or accuracy of this release.

Cision

View original content to download multimedia:http://www.prnewswire.com/news-releases/canntrust-establishes-us-operations-300870974.html

SOURCE CannTrust Holdings Inc.

View original content to download multimedia: http://www.newswire.ca/en/releases/archive/June2019/19/c7860.html

or to arrange an interview, please contact: Media Relations: Riya Dhaliwal, Tel: 1-888-677-1477, media@canntrust.ca; Investor Relations: Marc Charbin, 416-467-5229, investor@canntrust.caCopyright CNW Group 2019

Published at Wed, 19 Jun 2019 11:36:42 +0000

Body and Mind Inc. Expands Management Team and Commences California Manufacturing

Body and Mind Inc. Expands Management Team and Commences California Manufacturing

Body and Mind Inc. (CSE: BAMM) (OTC Pink: BMMJ) (the “Company” or “BaM”), a multi-state operator in California, Nevada, Ohio and Arkansas is pleased to announce it has commenced manufacturing in California through the Body and Mind California subsidiary NMG Cathedral City (“NMG”).

The company is proud to announce expansion of the management team with the appointment of Sophia Hase as general manager of the Cathedral City manufacturing operations.

“Sophia’s experience in operating a large cannabis manufacturing operation combined with her extensive training on best of class ERP (enterprise resource planning) systems are anticipated to move manufacturing at Cathedral City forward rapidly.” commented Robert Hasman, President of NMG Nevada and director of Body and Mind.” Sophia’s career in the health care industry and hands on experience with cannabis operations are expected to allow us to ramp up quickly and bring our popular Body and Mind brands to California.”

The Cathedral City facility has been producing THC distillate in bulk form since June 2018. The facility is planned to be outfitted to manufacture popular Body and Mind products including oils, wax, live resin, ambrosia and edibles.

In addition to the state-of-the-art ethanol and BHO extraction equipment, Body and Mind has ordered the wiped-film distillation system engineered by Mr. Atomizer. The platform uses a patented cascading design to process more material in less time and with less labor to increase production and revenues. The increased production capacity is anticipated to create efficiencies and grow revenues.

Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

For further information, please contact:

Michael Mills
Tel: 800-361-6312
mmills@bamcannabis.com

About Body and Mind Inc.

BaM is a well capitalized publicly traded company investing in high quality medical and recreational cannabis cultivation, manufacturing and retail. Our wholly owned Nevada subsidiary was awarded one of the first medical marijuana cultivation licences and holds cultivation and manufacturing licenses. BaM products include dried flower, edibles, oils and extracts as well as GPEN Gio cartridges and Lucid Mood offerings. BaM cannabis strains have won numerous awards including the 2019 Las Vegas Weekly Bud Bracket, Las Vegas Hempfest Cup 2016, High Times Top Ten, the NorCal Secret Cup and the Emerald Cup.

BaM continues to expand operations in Nevada, Arkansas, Ohio and investment in California and is dedicated to increasing shareholder value by focusing time and resources on improving operational efficiencies, facility expansions, state licensing opportunities as well as mergers and acquisitions.

Please visit www.bamcannabis.com for more information.

Safe Harbor Statement

Except for the statements of historical fact contained herein, the information presented in this news release constitutes “forward-looking statements” as such term is used in applicable United States and Canadian laws. These statements relate to analyses and other information that are based on forecasts of future results, estimates of amounts not yet determinable and assumptions of management. Any other statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions or future events or performance (often, but not always, using words or phrases such as “expects” or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans, “estimates” or “intends”, or stating that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved) are not statements of historical fact and should be viewed as “forward-looking statements”. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such risks and other factors include, among others, the actual results of activities, variations in the underlying assumptions associated with the estimation of activities, the availability of capital to fund programs and the resulting dilution caused by the raising of capital through the sale of shares, accidents, labor disputes and other risks. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements contained in this news release and in any document referred to in this news release.

Certain matters discussed in this news release and oral statements made from time to time by representatives of the Company may constitute forward-looking statements. Although the Company believes that the expectations reflected in such forward-looking statements are based upon reasonable assumptions, it can give no assurance that its expectations will be achieved. Forward-looking information is subject to certain risks, trends and uncertainties that could cause actual results to differ materially from those projected. Many of these factors are beyond the Company’s ability to control or predict. Important factors that may cause actual results to differ materially and that could impact the Company and the statements contained in this news release can be found in the Company’s filings with the Securities and Exchange Commission. The Company assumes no obligation to update or supplement any forward-looking statements whether as a result of new information, future events or otherwise. This press release shall not constitute an offer to sell or the solicitation of an offer to buy securities.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/45618

copyright (c) newsfile corp. 2019

Published at Fri, 14 Jun 2019 12:51:47 +0000